IDiyas

For the Inventor, By the Inventor

Thousand Oaks, CA, United States of America

Ning Chen

USPTO Granted Patents = 55 

 

Average Co-Inventor Count = 9.6

ph-index = 12

Forward Citations = 456(Granted Patents)

DiyaCoin DiyaCoin = 0.21 


Inventors with similar research interests:


Company Filing History:

goldMedal55 out of 1,970 
 
Amgen Inc.
 patents

Years Active: 2001-2025

where 'Filed Patents' based on already Granted Patents

55 patents (USPTO):
1. 12473289 - Heterocyclic compounds as delta-5 desaturase inhibitors and methods of use (2025-11-18),
2. 12440491 - KRAS G12C inhibitors and methods of using the same (2025-10-14),
3. 12083121 - Substituted piperazines as KRAS G12C inhibitors (2024-09-10),
4. 11993597 - Inhibitors of KRAS G12C and methods of using the same (2024-05-28),
5. 11766436 - KRAS G12C inhibitors and methods of using the same (2023-09-26),
6. 11548903 - Bicyclic thiazine and oxazine derivatives as beta-secretase inhibitors and methods of use (2023-01-10),
7. 11306087 - Inhibitors of KRAS G12C and methods of using the same (2022-04-19),
8. 11285156 - Substituted piperazines as KRAS G12C inhibitors (2022-03-29),
9. 11096939 - KRAS G12C inhibitors and methods of using the same (2021-08-24),
10. 11090304 - KRAS G12C inhibitors and methods of using the same (2021-08-17),
11. 11046680 - Heteroaryl-substituted triazoles as APJ receptor agonists (2021-06-29),
12. 11045484 - KRAS G12C inhibitors and methods of using the same (2021-06-29),
13. 11021493 - 1,4-thiazine dioxide and 1,2,4-thiadiazine dioxide derivatives as beta-secretase inhibitors and methods of use (2021-06-01),
14. 10947223 - Substituted oxazines as beta-secretase inhibitors (2021-03-16),
15. 10906890 - Triazole phenyl compounds as agonists of the APJ receptor (2021-02-02),

Title: Innovator Spotlight: Ning Chen and His Contributions to Cancer Treatment

Introduction: Ning Chen, based in Thousand Oaks, CA, has made significant strides in the field of medicinal chemistry and oncology. With an impressive portfolio of 53 patents, Chen is known for his innovative approaches to developing treatments for various cancers.

Latest Patents: Chen's most recent patents include groundbreaking work on KRAS G12C inhibitors. These inventions focus on providing compositions and methods for using these inhibitors to tackle disorders such as pancreatic, colorectal, and lung cancers. His contributions are vital in the ongoing battle against these aggressive diseases, making a meaningful impact on patient care.

Career Highlights: As a visionary at Amgen Inc., Ning Chen has been instrumental in advancing cancer research and treatment. His innovative spirit and dedication to finding effective solutions reflect his deep commitment to enhancing healthcare outcomes. His extensive patent portfolio showcases not just innovation but also a relentless pursuit of scientific excellence.

Collaborations: Throughout his career, Chen has collaborated with esteemed colleagues like Jennifer Rebecca Allen and Mark Henry Norman. These partnerships have facilitated significant advancements in their research initiatives and have enhanced the collective achievement in the realm of cancer therapeutics.

Conclusion: Ning Chen exemplifies the spirit of innovation and dedication in the pharmaceutical industry. His contributions, particularly in the area of KRAS G12C inhibitors, highlight the potential for new therapies in the treatment of cancer. As he continues to push boundaries through his research at Amgen Inc., the impact of his work will undoubtedly resonate across the medical community for years to come.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…